A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma

NCT01309412 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

9

Enrollment

INDUSTRY

Sponsor class

Stopped Protocol was stopped due to the safety issue in Global

Conditions

Multiple Myeloma

Interventions

DRUG: Siltuximab

Sponsor

Janssen Pharmaceutical K.K.